MHRA signals change for rare disease treatment regulation

The UK Medicines and Healthcare products Regulatory Agency has announced plans to update regulation for genomic therapies: read more on https://www.gov.uk/government/news/major-change-for-rare-disease-treatments-on-way-signals-mhra 

"The cost of delayed diagnosis and limited treatment options is estimated at £340 million annually, with a further £4.7 billion in health-related disability costs and a £14.9 billion annual loss to the economy. The paper published today sets out how the MHRA is thinking to change this. It commits the UK to major reform and is a huge signal that significant change for rare disease patients is on its way. " 

Direct link to policy paper: https://www.gov.uk/government/publications/rare-therapies-and-uk-regulatory-considerations